© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Derivatives

Top Section/Ad

Top Section/Ad

Most recent


The Americas derivatives community came together in New York to recognise and celebrate outstanding achievements across the industry
The derivatives market gathered in London on Thursday night to celebrate its leading players
SSA
Internal restrictions mean SSAs issue fewer CMS-linked notes
SSA
JP Morgan and Dutch pension fund PGGM transacted derivatives margin trade
More articles/Ad

More articles/Ad

More articles

  • Standard Chartered has decided to exit its equity derivatives and convertible bonds businesses in yet another move by the bank to bolster its performance by withdrawing from non-core operations.
  • The PBoC cut its benchmark interest rate and bank RRRs Friday but said the move did not amount to quantitative easing. Short-end swaps have been well offered in response and the curve has flattened. Sources have recommended watching currency market developments closely, writes Deirdre Yeung of Total Derivatives.
  • US federal regulators have approved a rule that will impose greater margin requirements on swaps that are not cleared through a clearing house, but have amended it to be less onerous for some transactions.
  • Fears that a disruptive weather pattern is forming in the Pacific Ocean look set to increase volatility in agricultural and energy markets, but the impact is unlikely to influence futures prices in the near-term.
  • European Central Bank president Mario Draghi said on Thursday he was prepared to cut interest rates and ramp up quantitative easing, creating a credit market rally that sent iTraxx Europe and Crossover indices back inside their levels before the end of September spike in volatility.
  • Wednesday’s shock market development saw short-selling research firm Citron allege that biotech firm Valeant Pharmaceutical inflated its sales figures by selling to “phantom captive pharmacies” in a plot reminiscent of the Enron scandal of over a decade ago.